QuickView: New improved antibodies
Xencor has demonstrated that its novel mAb technology can create superior versions of biologic blockbusters such as Humira, Xolair and Rituxan, albeit with early-stage data. At the 2014 ATS conference, XmAb7195 showed greater IgE clearance than Xolair in chimps and is now in Phase Ia in healthy and allergic subjects, with initial results by YE14. Phase Ib/IIa data for XmAb5871 in RA are due in H214. We believe the potential of Xencor's candidates more than justifies the EV of c $280m.Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat diseases with unmet medical needs. The company is developing a suite of clinical-stage drug candidates from its proprietary XmAb? technology platforms that are designed to treat cancer and autoimmune diseases. The company's protein engineering knowledge and the XmAb technologies are focused on the parts of the antibody that interacts with various segments of the immune system and controls antibody structure. This segment, referred to as the Fc domain, is constant and interchangeable among antibodies.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.